PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath - Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

January 08, 2021 23:00 - 1 hour

Go online to PeerView.com/VAY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss the most recent clinical evidence supporting modern antibody options in acute lymphoblastic leukemia (ALL), explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Upon completion of this activit...

Nathan H. Fowler, MD - Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL

January 08, 2021 23:00 - 1 hour

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval ...

Javed Butler, MD, MPH, MBA - Making the Case for Treating Iron Deficiency in Patients With Heart Failure

January 08, 2021 23:00 - 35 minutes

Go online to PeerView.com/BFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular diseases and heart failure (HF) research presents a patient case to explore current evidence-based recommendations for diagnosing iron deficiency (ID) to encourage timely and appropriate treatment to improve outcomes in patients with HF. Upon completion of this activity, participants should be better able to: Descri...

Jarushka Naidoo, MB, BCH, MHS / Andrew Stolbach, MD, MPH - Emergency Department on Alert: Solving Oncologic Emergency Quandaries During the Immuno-Oncology Era and COVID-19 Pandemic

January 06, 2021 23:00 - 1 hour

Go online to PeerView.com/NDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts provides effective and practical guidance on strategies and techniques for triaging, diagnosing, monitoring, and managing patients who present to the emergency department with immune-related adverse events, as well as special considerations for optimizing the management of oncologic emergencies during the COVID-19 pandemic. ...

Robin L. Jones, MD/ Kristen Ganjoo, MD/ Emanuela Palmerini, MD, PhD - Solutions for Tenosynovial Giant Cell Tumors: Employing Effective Multimodal and Multidisciplinary Approaches to Patient Care

January 06, 2021 23:00 - 56 minutes

Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity, participan...

Kathleen N. Moore, MD, MS / Kristi Jhangiani, PharmD, BCPS - Managed Care Implications of the Expanding Role of PARP Inhibitors in Oncology: Evolving Evidence Base, Current Value Assessment Frameworks, and Considerations for Decision-Making in Managed Care Settings

January 04, 2021 23:00 - 1 hour

Go online to PeerView.com/QQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PARP inhibitors have transformed the treatment of multiple cancers in recent years. Indeed, many agents have yielded promising clinical data and received regulatory approval for a number of solid tumors, providing newer alternatives for cancer patients, especially those with limited therapeutic options. Key clinical aspects associated with maximizing the potent...

Amit Singal, MD, MS - Unraveling the Intricacies of HCC Management With Your Multidisciplinary Team: A Closer Look at Effective Selection and Sequencing Strategies in an Expanding Treatment Landscape

January 04, 2021 23:00 - 1 hour

Go online to PeerView.com/CWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of hepatocellular carcinoma (HCC) is in the midst of a therapeutic paradigm shift. Partial hepatectomy, liver transplantation, ablation, radiation therapy, and embolization procedures remain important interventions for localized HCC, whereas sorafenib, a multikinase inhibitor, was the cornerstone of therapy for patients with extrahepatic disease....

Margaret von Mehren, MD - Personalizing and Prolonging Care in GIST: Expert Guidance on Integrating New TKI Strategies

January 04, 2021 23:00 - 58 minutes

Go online to PeerView.com/MER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Our understanding of the pathogenesis of GISTs was revolutionized by the discovery of KIT and PDGFRα mutations, which provided a diagnostic criteria and expanded treatment options. Tyrosine kinase inhibitors (TKIs), imatinib, sunitinib, and regorafenib ...

Naval Daver, MD / Harry P. Erba, MD, PhD / Tara Lin, MD / Gail J. Roboz, MD -How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics

January 04, 2021 23:00 - 1 hour

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts hig...

Toni K. Choueiri, MD / David F. McDermott, MD / Nizar M. Tannir, MD, FACP - At the Therapeutic Crossroads for RCC: Investigating the Current Applications, Controversies, and Future Use of Immunotherapy and Targeted Agents

January 04, 2021 23:00 - 1 hour

Go online to PeerView.com/QRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel targeted, immune-based, and tyrosine kinase inhibitors (TKIs) to the treatment armamentarium. Most recently, these advances have included the validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus target...

Josep Tabernero, MD, PhD - Optimizing Precision Medicine in Gastric Cancer Care

November 21, 2020 23:00 - 35 minutes

Go online to PeerView.com/QBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC-accredited video activity, Josep Tabernero, MD, PhD, gives his perspective on the latest evidence on novel HER2-targeted and other molecular-directed therapies in gastric cancer. Hear about recent data presented on gastric cancer and how precision medicine may improve gastric cancer patient care. Upon completion of this activity, participants sh...

Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists

November 17, 2020 23:00 - 59 minutes

Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A numb...

Naval Daver, MD / Joseph D. Khoury, MD, FCAP - The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes

November 13, 2020 23:00 - 1 hour

Go online to PeerView.com/PDK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist-oncologist panel discusses how modern, team-based treatment decisions are guided by the results of molecular/pathology testing across a wide range of acute myeloid leukemia (AML) settings, while also profiling how new evidence influences pathologic assessment and treatment selection across the continuum of AML care. Upon ...

Philip A. Thompson, MB, MS / William G. Wierda, MD, PhD - Achieving Innovation in CLL Care With BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum

November 09, 2020 23:00 - 1 hour

Go online to PeerView.com/ZJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologist-oncologists offers guidance on best practices for integrating Bruton’s tyrosine kinase (BTK) inhibitor options into chronic lymphocytic leukemia (CLL) treatment by presenting real-world clinical scenarios designed to illustrate cutting-edge treatment selection and sequencing strategies across the spectrum of CLL...

Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN - Visualizing the Potential Role of HIF-PH Inhibitors in the Treatment of Anemia in Chronic Kidney Disease

November 06, 2020 23:00 - 20 minutes

Go online to PeerView.com/KMS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic kidney disease (CKD) discusses anemia in CKD and explores the potential role of HIF-PH inhibitors in the treatment of this condition. Upon completion of this activity, participants will be able to: Identify the epidemiology, pathology, and burden of anemia associated with CKD, Discuss limitations of the c...

Robert Z. Orlowski, MD, PhD / Sagar Lonial, MD, FACP - The Rise of Novel Antibodies in Multiple Myeloma: Exploring the Present and Future of Antibody-Based Treatment From CD38 to BCMA

November 04, 2020 23:00 - 56 minutes

Go online to PeerView.com/BUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView “How I Think, How I Treat” CME video activity, multiple myeloma (MM) experts explore the era of antibody-based therapy and the implications of new science for treatment decisions from early disease settings through the management of relapsed/refractory MM. By sharing their personal insights and intra-institutional experiences, and combining the...

Madeline Couch, MSN, FNP-C / Suriya Jeyapalan, MD, MPH - A Clinician Guide to Tumor Treating Fields as a Fourth Modality in Cancer Treatment: Understanding the Science and Evidence and Implementing Critical Nursing Roles in Practice

November 04, 2020 23:00 - 58 minutes

Go online to PeerView.com/JAR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have eme...

Professor David I. Marks - Antibody Therapy in Acute Leukemia: Understanding Clinical Considerations for Use in Conjunction With HSCT

November 03, 2020 23:00 - 1 hour

Go online to PeerView.com/BYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity Professor David I. Marks, Farhad Ravandi, MD, and Matthias Stelljes, MD, give insights on the evidence behind the emergence of antibody therapy and its use in conjunction with HSCT in AML and ALL. These scientific MasterClass sessions are paired with a case-centered segment that illustrates therapeutic nuances such ...

Concetta (Connie) DiDomenico, RN, MSN, PNP-BC, CPHON / Michael J. Fisher, MD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1, Plexiform Neurofibromas, and Optic Pathway Gliomas: Improving Patient Outcomes With an Innovative Therapeutic Approach

November 03, 2020 23:00 - 1 hour

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, ...

George Plitas, MD - The Era of Immuno-Oncology in TNBC: Navigating Evidence in Early-Stage and Advanced Disease, Practicalities of Integration, and Implications for Breast Surgeons

November 02, 2020 23:00 - 1 hour

Go online to PeerView.com/JBC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy has become a new pillar in the treatment arsenal for advanced triple-negative breast cancer (TNBC), and accumulating evidence is supporting its expansion into earlier disease stages as well. To make the most of this therapeutic approach as a component of multimodal management of patients, especially in curative intent settings, it is increasingly ...

George Plitas, MD - Making the Most of the New Era of Immuno-Oncology in TNBC: Essential Guidance for Surgeons on How to Maximize the Potential of Immunotherapies and Combinations in Advanced and Early-Stage Breast Cancer

November 02, 2020 23:00 - 1 hour

Go online to PeerView.com/GKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapies are addressing a big unmet need in triple-negative breast cancer (TNBC) due to limited treatment options, the aggressive nature of the disease, and poor patient outcomes. This PeerView Live MasterClass and Practicum provides a comprehensive overview of the evolving role of immune checkpoint inhibitors in TNBC, specifically directed to surgeons. ...

Adam Brufsky, MD, PhD - Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: An Examination of the Evidence That Is Informing Real-World Practice

October 30, 2020 23:00 - 1 hour

Go online to PeerView.com/JTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts review the latest findings from randomized clinical trials as well as real-world studies assessing CDK 4/6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer, and discuss the complementary nature of clinical and real-world research and how data from both sources add to the body of evide...

Doris Quon, MD, PhD - Implementing Care With Extended Half-Life Factor VIII Therapy in Hemophilia A: An Interdisciplinary Conversation on Personalized Patient Management

October 28, 2020 23:00 - 32 minutes

Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the lates...

John M. Pagel, MD, PhD - Perspectives on Innovative Treatment for B-Cell Malignancies

October 22, 2020 23:00 - 1 hour

Go online to PeerView.com/BUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss therapeutic innovations in a range of B-cell cancers, including chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), and how community-based professionals can address the challenges of an increasingly complex B-cell cance...

Jennifer Wargo, MD, MMSc - Taking the Leap With Immunotherapy in Resectable Melanoma: Immune Checkpoint Inhibitors as Adjuvant and Neoadjuvant Therapy and Other Intersections With Surgical Management

October 21, 2020 23:00 - 1 hour

Go online to PeerView.com/NUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in melanoma explore evidence and practical lessons from major studies of adjuvant immunotherapy in melanoma, and provide insights on the future of immune checkpoint blockade in resectable disease. The panel also discusses real-world cases that illustrate how surgeons and oncologists can work together to identify ideal candidates for ch...

Gayle Jameson, RN, MSN, ACNP-BC, AOCN - Making Headway Toward Better Outcomes in Pancreatic Cancer: The Oncology Nurse as a Leader and Advocate for Patients in an Era of Advances in Care and Research

October 16, 2020 23:00 - 1 hour

Go online to PeerView.com/USV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the understanding of the science of pancreatic cancer have led to improved outcomes for patients with this traditionally difficult-to-treat malignancy, along with greater opportunities for oncology nurses to partner with patients and members of their cancer team to implement new standards of care. This CNE-certified activity, presented by PeerView i...

Sara M. Tinsley, PhD, APRN, AOCN / Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Meeting the Many Challenges of AML: Oncology Nurse Tactics in an Era of Novel Therapies

September 28, 2020 23:00 - 56 minutes

Go online to PeerView.com/TZV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology nurse experts discuss evidence on the safety and efficacy of novel therapeutics for the treatment of acute myeloid leukemia (AML) and, using a series of case scenarios, provide guidance on how to integrate innovative treatment options into the care of different AML populations. Upon completion of this activity, participants will be ab...

Brandon R. Allen, MD, FACEP / Anita Rajasekhar, MD, MS / Tung Wynn, MD- Ensuring the Rapid Recognition and Optimal Management of Hemophilia in the Emergency Department: The Role of Inclusive Decision-Making

September 23, 2020 23:00 - 1 hour

Go online to PeerView.com/QUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss available and emerging therapeutic approaches for the treatment of patients with hemophilia, as well as current guidelines and treatment protocols for patients with hemophilia presenting to the emergency department. Upon completion of this activity, participants will be able to: Assess current data on available an...

"Brandon R. Allen, MD, FACEP / Anita Rajasekhar, MD, MS / Tung Wynn, MD- Ensuring the Rapid Recognition and Optimal Management of Hemophilia in the Emergency Department: The Role of Inclusive Decision-Making"

September 23, 2020 23:00 - 1 hour

Go online to PeerView.com/QUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss available and emerging therapeutic approaches for the treatment of patients with hemophilia, as well as current guidelines and treatment protocols for patients with hemophilia presenting to the emergency department. Upon completion of this activity, participants will be able to: Assess current data on available an...

Edward Garon, MD, MS - Building on Progress to Further Advance Care for Patients With EGFR Mutation–Positive NSCLC: A Look at Emerging Precision Medicine Strategies Encompassing Acquired Resistance, Treatment Sequencing, and Patient Considerations

September 21, 2020 23:00 - 53 minutes

Go online to PeerView.com/MWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in thoracic oncology discuss the latest options for treatment of EGFR-mutated advanced NSCLC, including the rationale for and evidence supporting dual targeting of VEGF and EGFR pathways as well as the role of the first FDA approved combination of VEGF and EGFR inhibitors for newly diagnosed patients. Additionally, the experts explore ...

"Erika Hamilton, MD / Yelena Y. Janjigian, MD / Sandip Patel, MD / Nikhil Wagle, MD / - Moving in Leaps and Bounds Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, Gastrointestinal, Lung, and Other Cancers: Current Challenges, Opportunities for Improvement, and Practical Considerations"

September 17, 2020 23:00 - 1 hour

Go online to PeerView.com/VJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts explore the potential of the next wave of novel HER2-targeting therapies in various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. Watch as the panel share their insights into the data that support therapeutic targeting of HER2 and consider other critical research questions and future directi...

Erika Hamilton, MD / Yelena Y. Janjigian, MD / Sandip Patel, MD / Nikhil Wagle, MD / - Moving in Leaps and Bounds Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, Gastrointestinal, Lung, and Other Cancers: Current Challenges, Opportunities for Improvement, and Practical Considerations

September 17, 2020 23:00 - 1 hour

Go online to PeerView.com/VJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts explore the potential of the next wave of novel HER2-targeting therapies in various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. Watch as the panel share their insights into the data that support therapeutic targeting of HER2 and consider other critical research questions and future directi...

Ruben A. Mesa, MD, FACP - Following the Evidence to Effective Therapy for Myelofibrosis: How Clinicians Can Overcome Challenges in Patient Care in the JAK Inhibitor Era

September 15, 2020 23:00 - 1 hour

Go online to PeerView.com/GVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent approval of newer JAK inhibitors and new evidence on emerging JAK-targeting strategies have raised additional questions over optimized treatment selection in myelofibrosis (MF) and awareness of clinical factors that can influence therapeutic selection. Additionally, newer dynamic risk-assessment models have allowed for more precise characterization o...

Heather L. McArthur, MD, MPH - Harnessing the Immune System in the Treatment of Triple-Negative Breast Cancer to Maximize Benefits to Patients: State of the Science, Key Trials, Implications for Practice, and Patient-Centric Clinical Decision-Making

September 14, 2020 23:00 - 1 hour

Go online to PeerView.com/PHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of triple-negative breast cancer (TNBC) has remained challenging for many years, with limited effective options and poor outcomes for most patients. But the tide is turning, as new therapies are emerging for this patient population, with immunotherapy representing a new pillar of care in the treatment of TNBC. TNBC is known to be more immunogenic com...

George D. Demetri, MD - Modern Diagnostics and Targeted Therapy for TRK Fusion Cancers: Pathology-Oncologist Collaboration in the Era of Precision Medicine

September 11, 2020 23:00 - 1 hour

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate...

Heather L. McArthur, MD, MPH - Chair's Take on Harnessing the Immune System in the Treatment of TNBC and Beyond: Where Are We Now and Where Are We Going Next?

September 09, 2020 23:00 - 31 minutes

Go online to PeerView.com/KFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Dr. Heather McArthur provides a brief recap of how the emergence of checkpoint inhibitor therapy in TNBC has changed the management of this challenging subtype of breast cancer, and what some of the unanswered questions and controversies are that ongoing research is aiming to answer. Upon completion of this activity, participants should be bet...

Arjun Balar, MD - Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy

September 04, 2020 23:00 - 1 hour

Go online to PeerView.com/MMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in bladder cancer present real-world applications of emerging data for innovative therapeutics to offer practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Disc...

"Bradley J. Monk, MD, FACS, FACOG - Optimizing Precision Medicine in Ovarian Cancer: Expert Insights on Clinical Implications of PARP Inhibitor Therapy and Companion Diagnostics"

September 02, 2020 23:00 - 1 hour

Go online to PeerView.com/QYX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of PARP inhibitors and precise selection of patients using companion diagnostics have improved outcomes for patients with advanced ovarian cancer and provided new opportunities for oncologists to individualize care. In this activity, based on a recent live webcast, a panel of leading experts discuss the rationale behind the use of PARP inhibition in ...

Bradley J. Monk, MD, FACS, FACOG - Optimizing Precision Medicine in Ovarian Cancer: Expert Insights on Clinical Implications of PARP Inhibitor Therapy and Companion Diagnostics

September 02, 2020 23:00 - 1 hour

Go online to PeerView.com/QYX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of PARP inhibitors and precise selection of patients using companion diagnostics have improved outcomes for patients with advanced ovarian cancer and provided new opportunities for oncologists to individualize care. In this activity, based on a recent live webcast, a panel of leading experts discuss the rationale behind the use of PARP inhibition in ...

Josep Tabernero, MD, PhD - Optimizing Precision Medicine in Gastric Cancer Care: Essential Guidance on Translating Scientific Advances With Novel HER2-Targeted Therapies and Other Agents Into Current Clinical Practice

August 31, 2020 23:00 - 58 minutes

Go online to PeerView.com/VBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity, Josep Tabernero, MD, PhD; Geoffrey Ku, MD; and Kohei Shitara, MD, synthesize the latest data of emerging and available novel therapies and consider the future of gastric cancer care. These experts also examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating sc...

Emmanuel S. Antonarakis, MD - Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer: Rationale, Evidence, and Clinical Implications

August 28, 2020 23:00 - 44 minutes

Go online to PeerView.com/JEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Emmanuel S. Antonarakis, MD, discusses the rationale for targeting DNA repair defects through PARP inhibition and reviews recent safety and efficacy evidence with PARP inhibitors in patients with prostate cancer. He also highlights guidelines for genetic testing that is used to identify patients who might benefit from PARP inhibitor therapy an...

Linda R. Duska, MD, MPH - Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies

August 24, 2020 23:00 - 1 hour

Go online to PeerView.com/BTK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A panel of gynecologic oncology experts reviews the clinical evidence supporting the use of novel targeted, immunotherapeutic, and antibody-based strategies in gynecologic cancers. Learn the practical aspects of managing patients with advanced endometrial and cervical cancers and gain insight into experts’ in-clinic strategies for selecting the right treatment ...

Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

August 19, 2020 23:00 - 1 hour

Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with...

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

August 17, 2020 23:00 - 1 hour

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in...

Richard S. Finn, MD - Patient Stories From the HCC CaseBook: Expert Guidance on Optimizing Outcomes and Care With Newly Available and Emerging Therapies

August 14, 2020 23:00 - 1 hour

Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don’t miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importan...

David H. Ilson, MD, PhD - Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents

August 13, 2020 23:00 - 1 hour

Go online to PeerView.com/JQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The ability to personalize treatment for patients with gastric cancer has grown along with the improved understanding of the biologic rationale for therapeutic targeting. In this activity, based on a recent live webcast, an expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-direc...

Harry P. Erba, MD, PhD - Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations

August 12, 2020 23:00 - 1 hour

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulati...

William K. Oh, MD - How I Think, How I Treat: Learning to Navigate the Modern Prostate Cancer Landscape

August 10, 2020 23:00 - 1 hour

Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including se...

Alok A. Khorana, MD, FACP, FASCO - Teaming Up to Reduce the Burden of Cancer-Associated VTE: Applying the Latest Guidelines and Evidence in Gastrointestinal and Hematologic Malignancies and Other Cancer Settings

August 07, 2020 23:00 - 1 hour

Go online to PeerView.com/XDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A panel of hematology-oncology experts use the latest guidelines and real-world evidence to explore how the data have influenced clinical decision-making in cancer-associated VTE in different cancer settings. Using clinical scenarios and cases designed to build consensus, the experts illustrate how DOACs can be used to optimally integrate and implement evidence...

Unlocking the Benefits of Synergy Between Therapeutic Advances and Holistic Care in Gastric/GEJ Cancers: Current Evidence, Practical Guidance, and Point-of-Care Tools for Implementing a Multidisciplinary Approach to Modern Patient Care

August 06, 2020 23:00 - 1 hour

Go online to PeerView.com/BBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Targeted therapies have had a beneficial role in the advanced gastric or GEJ cancer setting, and several novel strategies of combining targeted therapy with immunotherapy are evolving the treatment landscape. While medicine continues to scientifically advance, the holistic care of patients with gastric/GEJ cancers is becoming more complex, and factors such as s...

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Episodes